# Supplementary Materials (business overview)



Medical Data Vision Co.,Ltd.

(Code: 3902)

May 12, 2022



### **Contents**



| 1 | About Our Business       | <br>3  |
|---|--------------------------|--------|
| 2 | Medical data held by MDV | <br>11 |
| 3 | Company Profile          | <br>15 |
|   |                          |        |

**Financial Results · Financial Statements** 

Copyright © Medical Data Vision Co,Ltd. All Rights Reserved.


20

medical.data.vision

### **About Our Business**

#### business model






### Our business journey



Steadily expanding business fields, sales, and scale in line with our corporate vision




### Change in sales weighting by service



### Data network crucial to data collection, turn data utilization into sales

Weighting of new businesses rising in part due to M&A



### Our strengths



## We possess the largest domestic stock of high-quality medical data in the rapidly growing medical big data market

### Business conditions

- Valuable big data (39.40mn patients) being collected from the Japanese medical frontline
- Aiming to raise medical care quality by building bonds of trust with major hospitals
- An overwhelming market share of around 45% in packaged products for DPC hospitals
- · Market which includes data utilization expected to grow fivefold over the next decade

#### **Business model**

- A hybrid model rooted in marketing capabilities as well as IT
- A business field with barriers to entry that are not easy to overcome
- Significant growth potential from expansion into data utilization services

### Earnings structure

- Main business model has strong profitability
- Data network service mostly a recurring revenue business, but a mixed recurring and nonrecurring business model in data utilization service gives the earnings structure balance

## Current business opportunities/challenges and the direction of growth



## Accelerating growth in data utilization service and planting the seeds for BtoC business

#### Data network service

#### **Opportunities**

#### **Challenges**

- System sales to smaller hospitals
- Room to expand the scope of subsidiary operations
- Drop in face-to-face marketing opportunities amid COVID
- Slow growth in new services

Data utilization service

- Market expansion, promote awareness of the benefits of data utilization
- Promote use outside the pharmaceutical sector
- Strengthen data using large stock of health insurance data (expand dataset)
- Further raise the pace of growth
- Hire more data analysis staff and expediting training

New businesses


- Lack of large-scale healthcare DB for citizens
- Growth prospects for BtoC healthcare business
- Establish business model for BtoC services
- · Accelerate links with SBI Group

\*Points in boldface relate to the parent company, other points relate to the MDV Group

### Direction of data network service



- 1 Focus on ongoing acquisition of data and expansion scope in DPC data business
- 2 Key to sales expansion in this service is the focus on new businesses




#### How can we develop the service?

- Maintain and develop links with medical institutions which can provide useful DPC data for the data utilization service
- · Gradually expand scope to real-time data via system upgrades to continually refresh and strengthen database
- Proactively challenge sizable markets as new business opportunities

#### Direction of data utilization service



- 1) Focus on growth rate due to expectations for market expansion
- 2 Expand pipeline as market awareness of MDV's data strength increases



[Keep growth rate to at least the speed of market expansion or higher]

→Continue to advance in the pharmaceutical sector, and proactively move into other spheres to compete with peers

#### How can we develop the service?


- Make the market aware of MDV's data strengths and the superiority of our model that uses an expanded dataset through newly-launched data unification
- Grow net client adds through pipeline expansion and expand services by increasing headcount
- Strengthen services not only for pharmaceutical companies' marketing, but also for drug discovery and life insurance companies


medical.data.vision


### Medical data held by MDV

#### Medical data held by MDV












### Medical database that has both quality and volume



No. of patients in medical database exceeds 39mn (39.40mn at end-Mar 2022)

Age distribution of database roughly matches Japan's population pyramid




Source: Based on the Population Projection for Japan (2017 survey), National Institute of Population and Social Security Research

#### Data users and example uses



14





#### **■** Example uses

- Post-marketing database studies
- Survey of drug prescription trends (by disease, by treatment department)
- Collection of promotional information, evidence extraction
- Target identification and analysis
- Analysis of disease onset factors
- Safety and efficacy validation, evidence extraction
- Feasibility studies
- ·Research-use data
- •Expanding drug applications etc.

medical.data.vision

### **Company Profile**

### **Company Profile (As of the end of December 2021)**



| Company<br>Name           | Medical Data Vision Co.,Ltd.   |  |  |  |  |  |  |  |
|---------------------------|--|--|--|--|--|--|--|--|
| Established               | August 20, 2003  |  |  |  |  |  |  |  |
| Head Office               | Sumitomo Fudosan Kanda Building 10F,<br>7 KandaMitoshirocho,Chiyoda-ku,Tokyo   |  |  |  |  |  |  |  |
| Number of<br>Employees    | 245 employees (Number of employees in the group)   |  |  |  |  |  |  |  |
| Capital                   | JPY 992,661,739  |  |  |  |  |  |  |  |
| President and C E O       | Hiroyuki Iwasaki   |  |  |  |  |  |  |  |
| TSE code /<br>TSE market  | 3902 / Tokyo Stock Exchange Prime Market<br>(Listed on Mothers market in December 16, 2014)  |  |  |  |  |  |  |  |
| M a j o r<br>Shareholders | SBI Holdings, Inc. (20.98%) MEDIPAL HOLDINGS CORPORATION (8.24%) Hiroyuki Iwasaki (President and CEO) (2.05%) CMIC HOLDINGS Co., Ltd. (1.56%) **Shareholding ratio excluding treasury shares |  |  |  |  |  |  |  |
| M a j o r<br>Subsidiaries | Doctorbook Inc.<br>System Be Alpha Co., Ltd.<br>MDV Trial Co., Ltd<br>Medical Domain Co., Ltd.   |  |  |  |  |  |  |  |


### Main group companies and business fields



| Company               | Business   |
|-----------------------|--|
| Medical Data Vision   | <ul> <li>Development, sale &amp; maintenance of<br/>management analysis systems</li> <li>Medical data analysis, surveys, consulting</li> </ul>                     |
| System Be Alpha       | <ul> <li>Development, sale &amp; maintenance of software including health consulting systems</li> <li>Agency sales for electronic medical records, etc.</li> </ul> |
| Doctorbook Doctorbook | ·Creation & operation of medical info video website  |
| Trial MDV Trial       | <ul><li>Data-based clinical trial business</li><li>SMO business</li></ul>  |
| *MDI Medical Domain   | <ul><li>Consultation support system</li><li>Development, sale &amp; maintenance of various data converters</li></ul>   |

## Group strategy: unification and utilization of medical and health data





### **Services overview**



#### [Data network service]

| Product      | Overview  | Price   |
|--------------|---|---|
| EVE          | Analysis of charges/DPC fee gap, patient #s/stay length/resources by disease/condition, and benchmarking with other hospitals  Uses benchmarks to identify user hospital's trends/strengths & weaknesses, helps with detailed investigation of treatment policy as core of hospital management  | Installation: Y4mn<br>Maintenance: Y50,000/mth. |
| Medical Code | Uses standardized format for DPC/elec. receipt data to support hospital management in areas like costing, raising treatment prices Unlimited user registration promotes smooth internal data sharing, change in awareness/actions to help improve management  | Installation: Y8.2mn Maintenance: Y100,000/mth. |
| MDV Act      | A cloud-based application that is the analytical gateway for existing products 'EVE' and 'Medical Code' and offers an at-a-glance view of key indicators for hospital management.  Allows benchmarking against other institutions on various indicators for DPC hospitals, regional integrated community care facilities, and convalescent facilities | Free (rollout of paid functionality planned)    |

#### [Data utilization service]

| Product                      | Overview   | Price                    |  |  |
|------------------------------|--|--------------------------|--|--|
| MDV analyzer                 | Online analysis tool allowing clients to easily examine data on patient numbers, prescription lengths/volumes using Japan's largest medical database  Enables multifaceted analysis based on actual medical practice | Y20mn/yr.                |  |  |
|                              | (surgery, testing) as well as disease and drug regimen   |                          |  |  |
| Medical data survey analysis | Provision of tailored reports in line with client's wishes   | Avg. Y3.5-4mn per survey |  |  |

medical.data.vision

### **Financial Results • Financial Statements**

### Sales breakdown by service, sales progress (cumulative) $_{ eal}$



|   |     | FY2019 |       |       | FY2020 |       |       | FY2021 |     |       | FY2022 |       |       |    |    |    |
|---|-----|--------|-------|-------|--------|-------|-------|--------|-----|-------|--------|-------|-------|----|----|----|
| (Millions of Yen)                       | 1Q  | 2Q     | 3Q    | 4Q    | 1Q     | 2Q    | 3Q    | 4Q     | 1Q  | 2Q    | 3Q     | 4Q    | 1Q    | 2Q | 3Q | 4Q |
| Data utilization<br>service total sales | 509 | 1,053  | 1,612 | 2,511 | 638    | 1,283 | 2,017 | 2,977  | 877 | 1,628 | 2,450  | 3,610 | 1,020 |    |    |    |
| MDV analyzer                            | 88  | 185    | 282   | 377   | 96     | 191   | 289   | 400    | 114 | 245   | 403    | 578   | 186   |    |    |    |
| Medical data<br>survey analysis         | 401 | 827    | 1,271 | 2,060 | 509    | 1,048 | 1,670 | 2,506  | 738 | 1,345 | 1,998  | 2,972 | 826   |    |    |    |
| Subsidiaries                            | 19  | 40     | 59    | 73    | 31     | 44    | 56    | 69     | 23  | 36    | 49     | 59    | 7     |    |    |    |
| Data network<br>service total sales     | 359 | 733    | 1,144 | 1,514 | 404    | 762   | 1,136 | 1,602  | 552 | 1,007 | 1,501  | 2,061 | 490   |    |    |    |
| Non-recurring                           | 105 | 221    | 342   | 407   | 65     | 109   | 145   | 220    | 68  | 107   | 151    | 252   | 67    |    |    |    |
| Recurring                               | 232 | 468    | 704   | 940   | 236    | 463   | 685   | 909    | 220 | 443   | 665    | 886   | 222   |    |    |    |
| Subsidiaries                            | 21  | 43     | 97    | 166   | 102    | 189   | 304   | 472    | 262 | 455   | 684    | 922   | 200   |    |    |    |

### **Business indicators**



22

| Main business indicators                          | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | 1Q FY2022 |
|---|--------|--------|--------|--------|--------|--------|-----------|
| Net sales (Ymn)                                   | 2,632  | 3,225  | 3,577  | 4,026  | 4,579  | 5,672  | 1,511     |
| Net sales growth (%)                              | 9.1    | 22.5   | 10.9   | 12.5   | 13.7   | 23.9   | 5.7       |
| Operating income (Ymn)                            | 430    | 569    | 351    | 809    | 1,146  | 1,594  | 470       |
| Ordinary income (Ymn)                             | 415    | 565    | 351    | 804    | 1,148  | 1,592  | 461       |
| Ordinary income margin (%)                        | 15.8   | 17.5   | 9.8    | 20.0   | 25.1   | 28.1   | 30.5      |
| Net income attributable to owners of parent (Ymn) | 178    | 354    | 69     | 554    | 700    | 1,087  | 313       |
| Net income per share (Y)                          | 4.67   | 8.86   | 1.74   | 13.85  | 17.72  | 27.74  | 8.17      |
| Net assets (Ymn)                                  | 2,809  | 3,164  | 3,278  | 4,023  | 4,136  | 4,205  | 2,960     |
| Total assets (Ymn)                                | 3,194  | 3,752  | 3,865  | 4,948  | 5,321  | 5,534  | 4,446     |
| Net assets per share (Y)                          | 70.22  | 79.08  | 81.91  | 99.68  | 104.00 | 106.69 | 75.99     |
| ROA (%)   | 13.7   | 16.3   | 9.2    | 18.3   | 22.4   | 29.3   | 9.2       |
| ROE (%)   | 6.7    | 11.9   | 2.2    | 15.3   | 17.3   | 26.3   | 9.5       |
| Equity-to-assent ratio (%)                        | 88.0   | 84.3   | 84.8   | 80.6   | 77.0   | 75.1   | 65.3      |
| CoGS (Ymn)  | 458    | 619    | 797    | 662    | 697    | 1,028  | 251       |
| SG&A (Ymn)  | 1,743  | 2,037  | 2,428  | 2,554  | 2,736  | 3,049  | 789       |

### Sales breakdown, other indicators, cash flow statement



| Sales breakdown (Ymn)     | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | 1Q FY2022 |
|---------------------------|--------|--------|--------|--------|--------|--------|-----------|
| Data network services     | 1,438  | 1,571  | 1,467  | 1,514  | 1,602  | 2,061  | 490       |
| Data utilization services | 1,194  | 1,654  | 2,110  | 2,511  | 2,977  | 3,610  | 1,020     |

| Other indicators   | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | 1Q FY2022 |
|--|--------|--------|--------|--------|--------|--------|-----------|
| No. of hospital using 'EVE'                                  | 791    | 799    | 801    | 802    | 772    | 770    | 753       |
| No. of hospitals using 'Medical Code'                        | 224    | 265    | 274    | 281    | 260    | 250    | 246       |
| No. of patients in MDV large-scale medical database (10,000) | 1,723  | 2,117  | 2,593  | 2,984  | 3,451  | 3,849  | 3,940     |

| Cash flow statement (Ymn)                           | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|--------|--------|--------|--------|--------|--------|
| Cash and cash equivalents at beginning of period    | 1,751  | 1,959  | 1,697  | 1,574  | 2,944  | 3,177  |
| CF from operating activities                        | 196    | 486    | 120    | 1,202  | 964    | 1,082  |
| CF from investing activities                        | -144   | -739   | -271   | -31    | -142   | -26    |
| CF from financing activities                        | 139    | -7     | 28     | 199    | -589   | -1,030 |
| Net increase(decrease) in cash and cash equivalents | 191    | -261   | -123   | 1,370  | 232    | 25     |
| Cash and cash equivalents at end of period          | 1,959  | 1,697  | 1,574  | 2,944  | 3,177  | 3,202  |

### **Balance sheet**



|                                  |            |            |            |            |            |            | medical.data.vision |
|----------------------------------|------------|------------|------------|------------|------------|------------|---------------------|
| Balance sheet (Ymn)              | End-FY2016 | End-FY2017 | End-FY2018 | End-FY2019 | End-FY2020 | End-FY2021 | 1Q FY2022           |
| Current assets                   | 2,797      | 2,864      | 2,773      | 3,872      | 4,319      | 4,525      | 2,738               |
| Cash and deposits                | 1,959      | 1,797      | 1,674      | 2,944      | 3,194      | 3,221      | 1,936               |
| Accounts receivable - trade      | 770        | 794        | 949        | 757        | 867        | 1,058      | 520                 |
| Raw materials                    | 9          | 13         | 15         | 12         | 34         | 11         | 7                   |
| Merchandise                      |            | 142        |            | _          | _          | _          | 0                   |
| Other                            | 57         | 116        | 134        | 179        | 224        | 235        | 276                 |
| Allowance for doubtful accounts  | -0         | -0         | -0         | -22        | -1         | -2         | -2                  |
| Non-current assets               | 394        | 888        | 1,091      | 1,076      | 1,002      | 1,009      | 1,708               |
| Property, plant and equipment    | 105        | 173        | 224        | 233        | 177        | 140        | 133                 |
| Intangible assets                | 127        | 476        | 368        | 356        | 303        | 227        | 690                 |
| Investments and other assets     | 161        | 238        | 498        | 486        | 521        | 641        | 883                 |
| Deferred assets                  | 2          | _          |            | _          | _          | _          | _                   |
| Total assets                     | 3,194      | 3,752      | 3,865      | 4,948      | 5,321      | 5,534      | 4,446               |
| Current liabilities              | 363        | 550        | 543        | 852        | 1,099      | 1,243      | 1,400               |
| Accounts payable - trade         | 39         | 40         | 28         | 33         | 76         | 97         | 85                  |
| Income taxes payable             | 80         | 188        | 164        | 138        | 298        | 400        | 57                  |
| Other                            | 243        | 321        | 350        | 679        | 725        | 746        | 1,257               |
| Non-current liabilities          | 20         | 37         | 43         | 71         | 84         | 85         | 85                  |
| Asset retirement obligations     | 18         | 33         | 38         | 71         | 72         | 72         | 72                  |
| Other                            | 1          | 4          | 4          | _          | 12         | 12         | 12                  |
| Total liabilities                | 384        | 588        | 587        | 924        | 1,184      | 1,328      | 1,485               |
| Shareholders' equity             | 2,809      | 3,164      | 3,278      | 3,989      | 4,100      | 4,156      | 2,902               |
| Share capital                    | 981        | 981        | 992        | 992        | 992        | 992        | 992                 |
| Capital surplus                  | 1,565      | 1,565      | 1,599      | 1,756      | 1,763      | 1,763      | 1,763               |
| Retained earnings                | 263        | 617        | 687        | 1,241      | 1,934      | 2,879      | 2,488               |
| Treasury shares                  | -0         | -0         | -0         | -0         | -590       | -1,479     | -2,341              |
| Total net assets                 | 2,809      | 3,164      | 3,278      | 4,023      | 4,136      | 4,205      | 2,960               |
| Total liabilities and net assets | 3,194      | 3,752      | 3,865      | 4,948      | 5,321      | 5,534      | 4,446               |



### **Contacts**

https://en.mdv.co.jp/application/contactus/form.php?TOP-

This document provides information intended solely to help readers' understanding of Medical Data Vision Co., Ltd. (MDV). Thus, MDV has no intention to solicit or encourage investment for securities or financial products mentioned in this document. Also, readers are advised that this document is not a disclosure document or statement of financial performance as required by Japan's Financial Instruments and Exchange Act, Act on Investment Trusts and Investment Corporations, related cabinet orders, cabinet office ordinances or rules, the rules governing companies listed on the Tokyo Stock Exchange, or any other applicable rules. This document contains forward-looking statements, including forecasts of financial position, results of operations, and business-related matters, as well as statements related to the plans and goals of the management of Medical Data Vision Co., Ltd. (MDV). There are a number of known and unknown risks and uncertainties that can cause MDV's actual results or performance to differ materially from any explicit or implicit forecasts contained herein. These forward-looking statements also rest on a number of assumptions with regard to MDV's present and future management strategies, as well as the political and economical environments in which MDV will conduct its future business operations. Although the information contained in this document is the best available at the time of publication, no assurances can be given regarding the accuracy, certainty, validity or fairness of this information. The content of this document can be modified or withdrawn without prior notice.